Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s):  MDNAF

Healthcare Biotechnology
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior... see more

Recent & Breaking News (TSX:MDNA)

Medicenna Announces Filing of Final Short Form Prospectus

Canada NewsWire October 11, 2019

Medicenna Announces Pricing of Marketed Offering of Units

Canada NewsWire October 2, 2019

Medicenna Announces Offering of Units

Canada NewsWire October 1, 2019

Medicenna Presented Promising Preclinical Results from its IL-2 Superkine Platform at the 5th Annual International Cancer Immunotherapy Conference

PR Newswire September 30, 2019

Nature Communications Publishes Studies on Medicenna's IL-2 Superkine Platform

Canada NewsWire September 26, 2019

Medicenna Presents Promising Update from its MDNA55 Clinical Trial in Recurrent Glioblastoma at the Targeting Innate Immunity Congress

Canada NewsWire September 25, 2019

Medicenna Strengthens Board of Directors by Appointment of Seasoned Biopharma Executive Ms. Karen Dawes

Canada NewsWire September 24, 2019

Medicenna to Present MDNA19 Pre-clinical Update at the 5th Annual International Cancer Immunotherapy Conference

Canada NewsWire September 17, 2019

Medicenna to Present Latest Data from the MDNA55 Clinical Trial in Recurrent Glioblastoma at the Targeting Innate Immunity Congress

Canada NewsWire September 12, 2019

Medicenna Reports First Quarter Fiscal 2020 Financial Results

Canada NewsWire August 9, 2019

Medicenna Selects its Lead Immuno-Oncology Clinical Candidate, MDNA19, from its IL-2 Superkine Platform

Canada NewsWire July 31, 2019

Medicenna Receives US $1.9 Million Non-Dilutive Grant Payment

Canada NewsWire July 9, 2019

MDNA55 Shows Promising Results in Models of Ovarian Cancer

Canada NewsWire June 26, 2019

Medicenna Announces March 31, 2019 Year-End Results

Canada NewsWire June 25, 2019

Medicenna Presents New Preclinical Results For its IL-2 Superkine Platform, MDNA109

Canada NewsWire June 20, 2019

Medicenna to Present at Raymond James Life Sciences and MedTech Conference

Canada NewsWire June 19, 2019

Medicenna Presents Preliminary Top-Line Clinical Results from their Phase 2b Trial of MDNA55 in Recurrent Glioblastoma

Canada NewsWire June 18, 2019

Medicenna To Host Key Opinion Leader Call Focused on MDNA55 Recurrent Glioblastoma Program and Preliminary Top-Line Results

Canada NewsWire June 13, 2019

Medicenna To Present Preliminary Top-Line Results on MDNA55 at the Immuno-Oncology Pharma Congress

Canada NewsWire June 5, 2019

Medicenna Presents Clinical Validation of the IL4 Receptor as a Biomarker for MDNA55 in Recurrent Glioblastoma

Canada NewsWire June 3, 2019